81187-01-1

Upstream product

• 80817-36-3 N-2-isobutyryl-5'-O-(dimethoxytrityl)-2'-deoxyguanosine 3'-(o-chlorophenyl β-cyanoethyl phosphate) 
• 68892-42-2 N-isobutyryl-2'-deoxyguanosine 
• 68892-41-1 5'-O-dimethoxytrityl-N-isobutyryldeoxyguanosine 
• 76958-62-8 [1,2,4]Triazol-1-yl-phosphonic acid (2R,3S,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(2-isobutyrylamino-6-oxo-1,6-dihydro-purin-9-yl)-tetrahydro-furan-3-yl ester 2-chloro-phenyl ester 
• 15074-54-1 2-chlorophenyl dichlorophosphate 
• 961-07-9 2'-Deoxyguanosine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 82921-42-4 2'-deoxy-N²-isobutyrylguanosine 3',5'-diisobutyrate 
• 72351-28-1 2-chlorophenyl phosphordi(1H-1-[1,2,4]triazolide) 

Downstream Products

• 78098-93-8 C₆₆H₆₃Cl₂N₉O₁₇P₂ 
• 85240-13-7 C₆₃H₆₀Cl₂N₈O₁₇P₂ 

Relevant academic research and scientific papers

DINUCLEOTIDE COMPOUNDS FOR TREATING CANCERS AND MEDICAL USES THEREOF

The present disclosure provides the dinucleotide compounds which is useful for treating various cancers. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating cancer. The present disclosure also provides a method of treatment of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment.

Simplified Liquid-Phase Preparation of Four Decadeoxyribonucleotides and their Preliminary Spectroscopic Characterization

Four self-complementary decadeoxyribonucleotides, dApTpApTpApTpApTpApT,dApTpApTpCpGpApTpApT, dApTpApTpGpCpApTpApT and dApApApApApTpTpTpTpT, were chemically synthesized by the phosphotriester procedure.Efforts were concentrated on keeping the procedure as simple as possible, concomitant with obtaining high-purity products at each step of the process.The decamers were elaborated from the 3'-end, starting with a 3'-O-benzoylated monomer according to the scheme: monomer + monomer -> dimer + dimer -> tetramer + dimer -> hexamer + tetramer -> decamer.Putity of intermediates and of the fully blocked decamers were monitored by chromatography and by 300-MHz 1H-NMR. spectroscopy.The deblocked decadeoxyribonucleotides were characterized by their UV., CD., and 1H-NMR. spectra.